For ER+ cancer, lymph node metastases were present in 60.9%, 54.8%, and 42.5% of BRCA2-carriers, young and older patients, respectively, whereas for ER-negative cancer the proportion with lymph node involvement was lowest in BRCA2-carriers and highest in young patients (Table 2b). This evidence concerns the gene BRCA2 and metastatic malignant neoplasm in the lymph nodes.